FINNENCE ▪ THE WIRE FILE
THE WIRE · № 54927
News▲ Bullish
ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics
KINDNews
DIRECTION▲ Bullish
SOURCES2
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN2026-09-29 11:09 UTC
LAST UPDATE2026-09-29 11:09 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A $446m RNA-therapeutics IPO signals reopening investor appetite for biotech new issues.
RNA biotech IPO tests investor appetite
CATALYST TO WATCH
Aftermarket performance and follow-on IPOs
MAIN RISK
Single IPO may not signal a durable window
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-09-29 11:09 UTC · LAST 2026-09-29 11:09 UTC2026-09-29 11:09 UTCNewsADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics - BioXconomyCURRENT RECORD
2026-09-29 11:09 UTCNewsADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics - bioxconomy.com
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program2026-09-29 11:30 UTC
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program2026-09-29 11:30 UTC
→CORRELATIONshares Healthcare
Smart ring maker Oura postpones public listing due to 'uncertainty in the IPO market'2026-09-29 11:30 UTC
Smart ring maker Oura postpones public listing due to 'uncertainty in the IPO market'2026-09-29 11:30 UTC
→CORRELATIONshares Healthcare
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
Smart Ring Maker Oura Delays IPO Due to Market ‘Uncertainty’2026-09-29 11:48 UTC
→CORRELATIONshares Healthcare
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)2026-09-29 12:03 UTC
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)2026-09-29 12:03 UTC
→CORRELATIONshares Healthcare
Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board2026-09-29 12:03 UTC
Professor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board2026-09-29 12:03 UTC
→CORRELATIONshares Healthcare
Commissioned report found lower total cost of care and reduced inpatient medical and surgical costs for Regence BlueShield members with access to Dispatch's Emergency Room Alternative Care Model2026-09-29 13:10 UTC
Commissioned report found lower total cost of care and reduced inpatient medical and surgical costs for Regence BlueShield members with access to Dispatch's Emergency Room Alternative Care Model2026-09-29 13:10 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.